Daratumumab in light chain deposition disease: rapid and profound hematologic response preserves kidney function

Blood Adv. 2020 Apr 14;4(7):1321-1324. doi: 10.1182/bloodadvances.2020001553.

Authors

Paolo Milani^{1

2}, Marco Basset^{1

2}, Paola Curci³, Andrea Foli^{1

2}, Rita Rizzi³, Mario Nuvolone^{1

2}, Raffaella Guido⁴, Loreto Gesualdo⁴, Giorgina Specchia³, Giampaolo Merlini^{1

2}, Giovanni Palladini^{1

2}

Affiliations

¹ Amyloidosis Research and Treatment Center, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy.
² Department of Molecular Medicine, University of Pavia, Pavia, Italy.
³ Hematology Unit, Bari Hospital, Bari, Italy; and.
⁴ Nephrology Unit, Bari University, Bari, Italy.

Abstract

Daratumumab is effective in treated light chain deposition disease.
Daratumumab can prevent progression of renal failure in these patients.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal
Humans
Kidney
Multiple Myeloma*

Substances

Antibodies, Monoclonal
daratumumab